AU2001255849A1 - PDE-V inhibitors for treatment of Parkinson's Disease - Google Patents

PDE-V inhibitors for treatment of Parkinson's Disease

Info

Publication number
AU2001255849A1
AU2001255849A1 AU2001255849A AU2001255849A AU2001255849A1 AU 2001255849 A1 AU2001255849 A1 AU 2001255849A1 AU 2001255849 A AU2001255849 A AU 2001255849A AU 2001255849 A AU2001255849 A AU 2001255849A AU 2001255849 A1 AU2001255849 A1 AU 2001255849A1
Authority
AU
Australia
Prior art keywords
pde
parkinson
inhibitors
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001255849A
Other versions
AU2001255849B2 (en
AU2001255849B8 (en
Inventor
H. H. Roylance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Icos LLC
Original Assignee
Lilly Icos, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US19818000P priority Critical
Priority to US60/198,180 priority
Application filed by Lilly Icos, Llc. filed Critical Lilly Icos, Llc.
Priority to PCT/US2001/040538 priority patent/WO2001078711A2/en
Publication of AU2001255849A1 publication Critical patent/AU2001255849A1/en
Application granted granted Critical
Publication of AU2001255849B2 publication Critical patent/AU2001255849B2/en
Publication of AU2001255849B8 publication Critical patent/AU2001255849B8/en
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2001255849A 2000-04-19 2001-04-17 PDE-V inhibitors for treatment of Parkinson's Disease Ceased AU2001255849B8 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US19818000P true 2000-04-19 2000-04-19
US60/198,180 2000-04-19
PCT/US2001/040538 WO2001078711A2 (en) 2000-04-19 2001-04-17 Pde-v inhibitors for treatment of parkinson's disease

Publications (3)

Publication Number Publication Date
AU2001255849A1 true AU2001255849A1 (en) 2002-01-17
AU2001255849B2 AU2001255849B2 (en) 2005-12-22
AU2001255849B8 AU2001255849B8 (en) 2006-04-27

Family

ID=22732318

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001255849A Ceased AU2001255849B8 (en) 2000-04-19 2001-04-17 PDE-V inhibitors for treatment of Parkinson's Disease
AU5584901A Pending AU5584901A (en) 2000-04-19 2001-04-17 Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU5584901A Pending AU5584901A (en) 2000-04-19 2001-04-17 Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease

Country Status (9)

Country Link
US (2) US20020006926A1 (en)
EP (1) EP1278522B1 (en)
JP (1) JP2004500425A (en)
CN (1) CN1436080A (en)
AT (1) AT343388T (en)
AU (2) AU2001255849B8 (en)
CA (1) CA2407031A1 (en)
DE (1) DE60124085D1 (en)
WO (1) WO2001078711A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
AU2002324846B2 (en) 2001-08-31 2007-05-10 Childrens Hospital Medical Center Phosphodiesterase activity and regulation of phosphodiesterase 1-B-mediated signaling in brain
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
ES2645371T3 (en) 2005-06-06 2017-12-05 Intra-Cellular Therapies, Inc. organic compounds
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CA2651519A1 (en) * 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
WO2008063505A1 (en) * 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
EP2155182A2 (en) * 2007-05-18 2010-02-24 Vivus, Inc. Novel compositions comprising a phosphodiesterase-5 inhibitor and their use in methods of treatment
PT2240490E (en) * 2007-12-06 2013-12-09 Takeda Pharmaceutical Organic compounds
EP2240028B1 (en) * 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
MX2010013393A (en) 2008-06-06 2011-06-21 Pharma Two B Ltd Pharmaceutical compositions for treatment of parkinson's disease.
CN102238873A (en) 2008-12-06 2011-11-09 细胞内治疗公司 Organic compounds
ES2551325T3 (en) 2008-12-06 2015-11-18 Intra-Cellular Therapies, Inc. organic compounds
EP2367429B1 (en) 2008-12-06 2017-06-07 Intra-Cellular Therapies, Inc. Organic compounds
KR20110096032A (en) 2008-12-06 2011-08-26 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
NZ593033A (en) * 2008-12-06 2013-11-29 Intra Cellular Therapies Inc 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine and 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine derivatives as PDE1 Inhibitors
JP2012526810A (en) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP5894148B2 (en) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
JP6051210B2 (en) * 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
WO2013016662A1 (en) * 2011-07-28 2013-01-31 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
JP6549040B2 (en) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. New use
KR20150131320A (en) 2013-03-15 2015-11-24 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
WO2015106032A1 (en) 2014-01-08 2015-07-16 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
BR112017005533A2 (en) 2014-09-17 2017-12-05 Intra Cellular Therapies Inc COMPOUNDS and METHODS
CA2969594A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
KR20170089001A (en) 2014-12-06 2017-08-02 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018160067A1 (en) * 2017-03-02 2018-09-07 Universiteit Van Amsterdam Specific increase of dopamine synthesis through targeting of the guanylate cyclase 2c receptor in the treatment of parkinson's disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147789A (en) * 1974-03-14 1979-04-03 Sandoz Ltd. 6-Methyl-8-thiomethyl-ergolene derivatives
ES2333691T3 (en) 1993-05-27 2010-02-26 Board Of Regents Of The University Of Washington Union to gmp cyclic, phosphodesterase materials specific to gmp cycles and methods.
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
IL124969A (en) * 1995-12-28 2002-09-12 Fujisawa Pharmaceutical Co Benzimidazole derivatives, processes for their preparation and pharmaceutical compositions containing them
KR20000010918A (en) 1996-05-10 2000-02-25 게리 엘. 윌콕스 Carboline derivative
AU739417B2 (en) 1997-05-29 2001-10-11 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection dysfunction
JP2002509553A (en) 1997-10-27 2002-03-26 藤沢薬品工業株式会社 Tricyclic compounds as cGMP-PDE inhibitors
PT1049695E (en) 1997-11-12 2002-07-31 Bayer Ag Imidazotriazinones 2-phenyl substituted as phosphodiesterase inhibitors
AU5067098A (en) 1997-11-26 1999-06-15 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives with cgmp-pde inhibitory activity
DE19752952A1 (en) 1997-11-28 1999-06-02 Merck Patent Gmbh thienopyrimidines
ZA9810766B (en) 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
IL136603D0 (en) * 1997-12-12 2001-06-14 Cell Pathways Inc N-benzyl-3-indenylacetamide derivatives for treating neoplasia
CA2302943C (en) 1998-02-19 2007-08-07 Eisai Co., Ltd. Phthalazine compounds and therapeutic agents for erectile dysfunction
TR200003039T2 (en) * 1998-04-20 2001-01-22 Pfizer Inc. pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
HU0101793A3 (en) 1998-04-20 2003-02-28 Fujisawa Pharmaceutical Co Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
AU775102B2 (en) * 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology

Similar Documents

Publication Publication Date Title
DE60116313D1 (en) Compounds for the treatment of alzheimer's disease
DE60124080D1 (en) Compounds and method for the treatment of alzheimer's disease
DE60124302D1 (en) Thiazone derivatives for the treatment of ppar-life diseases
DK1443955T3 (en) PDGF-BB for the treatment of Parkinson's disease
AU780006C (en) Azacyclic compounds for use in the treatment of serotonin related diseases
AU784374C (en) Synthesis of 2'-deoxy-L-nucleosides
HK1091815A1 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
AU2001247905A1 (en) 2-alkylidene-19-nor-vitamin D compounds and their therapeutic uses
AU2002217082A1 (en) Mixtures or organic compounds for the treatment of airway diseases
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
DE60100595D1 (en) Improved transdermal therapeutic system for the treatment of parkinson's disease
AU2001262957A1 (en) Drug combinations useful for prevention of restenosis
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
AU1294401A (en) Methods for treating fibroproliferative diseases
AUPR638101A0 (en) Composition and method for treatment of disease
AU2003267203A1 (en) Method for administering thermotherapy to prevent the growth of tumors
AU8287401A (en) Quinuclidine-substituted aryl compounds for treatment of disease
AU2001274109A1 (en) Method of administering bisphosphonates
AU2002326589A1 (en) Compositions and methods for the prevention and treatment of Huntington's disease
SI1303272T1 (en) Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease
AU2003259249A1 (en) Pyridazinylpiperazine derivatives for treating pain
AU2001268363A1 (en) Treatment of B cell associated diseases
AU2001261580A1 (en) Delivery devices for treatment of vascular disease
AU2001259774A1 (en) Delivery devices for treatment of vascular disease